Patient‐derived xenograft models of non‐small cell lung cancer for evaluating targeted drug sensitivity and resistance
Kenji Kita(Kai Research (United States)), Seiji Yano(Kanazawa University Hospital)
Cited by 50
Related Papers
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
|Nature Communications|2019|360
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
|Human Molecular Genetics|2004|174
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
|Nature Communications|2020|112